186 related articles for article (PubMed ID: 16827816)
1. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
Li KM; Rivory LP; Hoskins J; Sharma R; Clarke SJ
Br J Clin Pharmacol; 2007 Jan; 63(1):67-74. PubMed ID: 16827816
[TBL] [Abstract][Full Text] [Related]
2. Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Li KM; Rivory LP; Clarke SJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jun; 820(1):121-30. PubMed ID: 15866500
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
5. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei D; Groshen S; Lenz HJ
Int J Colorectal Dis; 2002 Jan; 17(1):46-9. PubMed ID: 12018454
[TBL] [Abstract][Full Text] [Related]
7. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
8. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
Garcia AA; Blessing JA; Darcy KM; Lenz HJ; Zhang W; Hannigan E; Moore DH
Gynecol Oncol; 2007 Mar; 104(3):572-9. PubMed ID: 17049588
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
[TBL] [Abstract][Full Text] [Related]
11. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
12. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
[TBL] [Abstract][Full Text] [Related]
13. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R
J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782
[TBL] [Abstract][Full Text] [Related]
15. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
16. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Lokich J
Cancer Invest; 2004; 22(5):713-7. PubMed ID: 15581052
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
20. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
